Health Care, and more specifically oncology, will continue to gain attention with the events on the calendar this week.

The Sachs 20th Annual Biotech in Europe Forum runs from Monday to Thursday. 

Monday, morning, Amgen (NASDAQ:AMGN) will present results from a Phase 1 Study of AMG 160 for prostate cancer as part of the European Society of Medical Oncology Virtual Congress.

And Tuesday morning, Merck, whose oncology division has outperformed competitors over the last few years, is hosting an Oncology Virtual IR Briefing as part of ESMO 2020, according to Seeking Alpha’s Catalyst Watch.

A wave of deals in the cancer-treatment space has sparked sharp rallies across biotech

The big trigger last week was Gilead Sciences (NASDAQ:GILD) agreeing to acquire Immunomedics (NASDAQ:IMMU) in a transaction that values Immunomedics at ~$21B, giving Gilead Trodelvy, used to treat certain forms of breast cancer and being evaluated for a number of other cancers.

On Friday, Piper Sandler issued a list of biotechs that could be in the sights of acquirers for their oncology treatment. Those companies have assets that are “largely de-risked and target high value indications”, Piper Sandler said

On the list: Allogene Therapeutics (NASDAQ:ALLO), ALX Oncology (NASDAQ:ALXO), Aptose Biosciences (NASDAQ:APTO), Blueprint Medicines (NASDAQ:BPMC), Clovis (NASDAQ:CLVS), Deciphera (NASDAQ:DCPH), Fate Therapeutics (NASDAQ:FATE), IGM Biosciences (NASDAQ:IGMS), ImmunoGen (NASDAQ:IMGN), Incyte (NASDAQ:INCY), Iovance Biotherapeutics (NASDAQ:IOVA), iTeos Therapeutics (NASDAQ:ITOS), Kura Oncology (NASDAQ:KURA), Mirati Therapeutics (NASDAQ:MRTX), Seattle Genetics (NASDAQ:SGEN), Sutro Biopharma (NASDAQ:STRO), Syros Pharmaceuticals (NASDAQ:SYRS), TCR2 Therapeutics (NASDAQ:TCRR) and Xencor (NASDAQ:XNCR).

The Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) jumped 11.2% last week, compared with a decline of less than 1% in the broader market and rise of less than 1% in the health care sector. It ended the week at $29.08, a new all-time closing high, as it surged past the previous high set in late July.

CNCR is now up 17.4% from its recent low set a mere two weeks ago when it troughed around May levels.

Taking a technical look at CNCR’s momentum, the relative strength index is at 69.21, hovering just below overbought territory. Its RSI hasn’t been above 70 since May 18.

From the lows set on Sept. 8, the ETF is has plowed through its 10-, 50- and 100-day simple moving averages. The most important break was when it breached the 50-day SMA to the upside on Sept. 14. The 50-day SMA had been acting as a solid resistance level since late July.

Looking to the overall sector, the SPDR Health Care Sector ETF (NYSEARCA:XLV) rose 0.9% last week, but is still down 1.7% in the last month.

The defensive sector has not seen any benefits from the move in cash out of technology and momentum stocks in September. It’s down 3.6% form its recent highs on Sept. 2, the same day that the big tech selling accelerated.

XLV sits just below its 50-day SMA of $106.03 and has had a couple failed upside tests of that level since Sept. 8. But it’s also not far above its 100-day at $103.15 and 200-day at $100.4. 



Source link

Comments to: Sector Watch: More oncology events as cancer ETF breaks out (NASDAQ:CNCR)

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.